54 related articles for article (PubMed ID: 38664331)
21. Multicenter randomised trial of two versus three courses of preoperative cisplatin and fluorouracil plus docetaxel for locally advanced oesophageal squamous cell carcinoma.
Makino T; Yamasaki M; Tanaka K; Yamashita K; Urakawa S; Ishida T; Shiraishi O; Sugimura K; Miyata H; Motoori M; Fujitani K; Takeno A; Hirao M; Kimura Y; Satoh T; Yano M; Eguchi H; Doki Y; Yasuda T
Br J Cancer; 2022 Jun; 126(11):1555-1562. PubMed ID: 35140339
[TBL] [Abstract][Full Text] [Related]
22. Impact of CT-assessed changes in tumor size after neoadjuvant chemotherapy on pathological response and survival of patients with esophageal squamous cell carcinoma.
Matsumoto S; Wakatsuki K; Nakade H; Kunishige T; Miyao S; Tsujimoto A; Tatsumi T; Sho M
Langenbecks Arch Surg; 2022 May; 407(3):965-974. PubMed ID: 34989856
[TBL] [Abstract][Full Text] [Related]
23. Evaluating the effect of Neoadjuvant chemotherapy for esophageal Cancer using the RECIST system with shorter-axis measurements: a retrospective multicenter study.
Taniyama Y; Murakami K; Yoshida N; Takahashi K; Matsubara H; Baba H; Kamei T
BMC Cancer; 2021 Sep; 21(1):1008. PubMed ID: 34496769
[TBL] [Abstract][Full Text] [Related]
24. Randomized Phase II Study of PET Response-Adapted Combined Modality Therapy for Esophageal Cancer: Mature Results of the CALGB 80803 (Alliance) Trial.
Goodman KA; Ou FS; Hall NC; Bekaii-Saab T; Fruth B; Twohy E; Meyers MO; Boffa DJ; Mitchell K; Frankel WL; Niedzwiecki D; Noonan A; Janjigian YY; Thurmes PJ; Venook AP; Meyerhardt JA; O'Reilly EM; Ilson DH
J Clin Oncol; 2021 Sep; 39(25):2803-2815. PubMed ID: 34077237
[TBL] [Abstract][Full Text] [Related]
25. Two versus three courses of preoperative cisplatin and fluorouracil plus docetaxel for treating locally advanced esophageal cancer: short-term outcomes of a multicenter randomized phase II trial.
Shiraishi O; Makino T; Yamasaki M; Tanaka K; Yamashita K; Ishida T; Sugimura K; Miyata H; Motoori M; Fujitani K; Takeno A; Hirao M; Kimura Y; Satoh T; Yano M; Doki Y; Yasuda T
Esophagus; 2021 Oct; 18(4):825-834. PubMed ID: 33738656
[TBL] [Abstract][Full Text] [Related]
26. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries.
Sung H; Ferlay J; Siegel RL; Laversanne M; Soerjomataram I; Jemal A; Bray F
CA Cancer J Clin; 2021 May; 71(3):209-249. PubMed ID: 33538338
[TBL] [Abstract][Full Text] [Related]
27. Pathological Regression of Lymph Nodes Better Predicts Long-term Survival in Esophageal Cancer Patients Undergoing Neoadjuvant Chemotherapy Followed by Surgery.
Hagi T; Makino T; Yamasaki M; Yamashita K; Tanaka K; Saito T; Takahashi T; Kurokawa Y; Motoori M; Kimura Y; Nakajima K; Morii E; Eguchi H; Doki Y
Ann Surg; 2022 Jun; 275(6):1121-1129. PubMed ID: 32910622
[TBL] [Abstract][Full Text] [Related]
28. Preoperative cisplatin, fluorouracil, and docetaxel with or without radiotherapy after poor early response to cisplatin and fluorouracil for resectable oesophageal adenocarcinoma (AGITG DOCTOR): results from a multicentre, randomised controlled phase II trial.
Barbour AP; Walpole ET; Mai GT; Barnes EH; Watson DI; Ackland SP; Martin JM; Burge M; Finch R; Karapetis CS; Shannon J; Nott LM; Varma S; Marx G; Falk GL; Gebski V; Oostendorp M; Wilson K; Thomas J; Lampe G; Zalcberg JR; Simes J; Smithers BM;
Ann Oncol; 2020 Feb; 31(2):236-245. PubMed ID: 31959340
[TBL] [Abstract][Full Text] [Related]
29. Molecular Barcode Sequencing for Highly Sensitive Detection of Circulating Tumor DNA in Patients with Esophageal Squamous Cell Carcinoma.
Hagi T; Kurokawa Y; Takahashi T; Saito T; Yamashita K; Tanaka K; Makino T; Yamasaki M; Nakajima K; Mori M; Doki Y
Oncology; 2020; 98(4):222-229. PubMed ID: 31846968
[TBL] [Abstract][Full Text] [Related]
30. Dysphagia Score as a Predictor of Adverse Events Due to Triplet Chemotherapy and Oncological Outcomes in 434 Consecutive Patients with Esophageal Cancer.
Hagi T; Makino T; Yamasaki M; Tanaka K; Nishida N; Sakai D; Motoori M; Kimura Y; Satoh T; Mori M; Doki Y
Ann Surg Oncol; 2019 Dec; 26(13):4754-4764. PubMed ID: 31452051
[TBL] [Abstract][Full Text] [Related]
31. Lymph Node Response to Neoadjuvant Chemotherapy as an Independent Prognostic Factor in Metastatic Esophageal Cancer.
Urakawa S; Makino T; Yamasaki M; Tanaka K; Miyazaki Y; Takahashi T; Kurokawa Y; Motoori M; Kimura Y; Nakajima K; Mori M; Doki Y
Ann Surg; 2021 Jun; 273(6):1141-1149. PubMed ID: 31274656
[TBL] [Abstract][Full Text] [Related]
32. Comparative Molecular Analyses of Esophageal Squamous Cell Carcinoma, Esophageal Adenocarcinoma, and Gastric Adenocarcinoma.
Salem ME; Puccini A; Xiu J; Raghavan D; Lenz HJ; Korn WM; Shields AF; Philip PA; Marshall JL; Goldberg RM
Oncologist; 2018 Nov; 23(11):1319-1327. PubMed ID: 29866946
[TBL] [Abstract][Full Text] [Related]
33. Metabolic Tumor Volume Change Predicts Long-term Survival and Histological Response to Preoperative Chemotherapy in Locally Advanced Esophageal Cancer.
Makino T; Yamasaki M; Tanaka K; Masuike Y; Tatsumi M; Motoori M; Kimura Y; Hatazawa J; Mori M; Doki Y
Ann Surg; 2019 Dec; 270(6):1090-1095. PubMed ID: 29727327
[TBL] [Abstract][Full Text] [Related]
34. Machine Learning for Medical Imaging.
Erickson BJ; Korfiatis P; Akkus Z; Kline TL
Radiographics; 2017; 37(2):505-515. PubMed ID: 28212054
[TBL] [Abstract][Full Text] [Related]
35. Feasibility of Preoperative Chemotherapy with Docetaxel, Cisplatin, and 5-Fluorouracil versus Adriamycin, Cisplatin, and 5-Fluorouracil for Resectable Advanced Esophageal Cancer.
Shiraishi O; Yamasaki M; Makino T; Motoori M; Miyata H; Shinkai M; Kimura Y; Hirao M; Fujitani K; Tamura S; Kobayashi K; Yano M; Doki Y; Yasuda T
Oncology; 2017; 92(2):101-108. PubMed ID: 27907921
[TBL] [Abstract][Full Text] [Related]
36. Multicenter randomized phase II study of cisplatin and fluorouracil plus docetaxel (DCF) compared with cisplatin and fluorouracil plus Adriamycin (ACF) as preoperative chemotherapy for resectable esophageal squamous cell carcinoma (OGSG1003).
Yamasaki M; Yasuda T; Yano M; Hirao M; Kobayashi K; Fujitani K; Tamura S; Kimura Y; Miyata H; Motoori M; Shiraishi O; Makino T; Satoh T; Mori M; Doki Y
Ann Oncol; 2017 Jan; 28(1):116-120. PubMed ID: 27687307
[TBL] [Abstract][Full Text] [Related]
37. Somatic mutations in plasma cell-free DNA are diagnostic markers for esophageal squamous cell carcinoma recurrence.
Ueda M; Iguchi T; Masuda T; Nakahara Y; Hirata H; Uchi R; Niida A; Momose K; Sakimura S; Chiba K; Eguchi H; Ito S; Sugimachi K; Yamasaki M; Suzuki Y; Miyano S; Doki Y; Mori M; Mimori K
Oncotarget; 2016 Sep; 7(38):62280-62291. PubMed ID: 27556701
[TBL] [Abstract][Full Text] [Related]
38. Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial.
Shapiro J; van Lanschot JJB; Hulshof MCCM; van Hagen P; van Berge Henegouwen MI; Wijnhoven BPL; van Laarhoven HWM; Nieuwenhuijzen GAP; Hospers GAP; Bonenkamp JJ; Cuesta MA; Blaisse RJB; Busch ORC; Ten Kate FJW; Creemers GM; Punt CJA; Plukker JTM; Verheul HMW; Bilgen EJS; van Dekken H; van der Sangen MJC; Rozema T; Biermann K; Beukema JC; Piet AHM; van Rij CM; Reinders JG; Tilanus HW; Steyerberg EW; van der Gaast A;
Lancet Oncol; 2015 Sep; 16(9):1090-1098. PubMed ID: 26254683
[TBL] [Abstract][Full Text] [Related]
39. Early response to neoadjuvant chemotherapy in advanced esophageal cancer evaluated by computed tomography predicts the utility of a second cycle of chemotherapy.
Motoori M; Yano M; Yasuda T; Miyata H; Peng Y; Yamasaki M; Shiraishi O; Tanaka K; Ishikawa O; Shiozaki H; Doki Y
Mol Clin Oncol; 2013 May; 1(3):521-526. PubMed ID: 24649204
[TBL] [Abstract][Full Text] [Related]
40. Inter-observer reproducibility of semi-automatic tumor diameter measurement and volumetric analysis in patients with lung cancer.
Dinkel J; Khalilzadeh O; Hintze C; Fabel M; Puderbach M; Eichinger M; Schlemmer HP; Thorn M; Heussel CP; Thomas M; Kauczor HU; Biederer J
Lung Cancer; 2013 Oct; 82(1):76-82. PubMed ID: 23932487
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
